. Author manuscript; available in PMC: 2018 Feb 1.

Published in final edited form as: Adv Drug Deliv Rev. 2016 Apr 1;110-111:3–12. doi: 10.1016/j.addr.2016.03.008

Table 2.

Co-administration of tumor-penetrating peptide together with drugs in treatment studies.

Drug-peptide combinations

Reference	Peptide	Drug	Tumor model
[25]	RGD	Nab-paclitaxel, doxorubicin, doxorubicin liposomes, trastuzumab	22Rv1 human prostate cancer and BT474 human breast cancer xenografts
[72]	iRGD	Cisplatin in naoparticles	A549 human non-small cell lung carcinoma xenograft
[26]	iRGD	Gemcitabine	Pancreatic adenocarcinoma models
[73]	iRGD	Gemcitabine	A549 human non-small cell lung carcinoma xenograft
[28]	iRGD	Doxorubicin, sorafenib	HepG2 and Hu-7 human hepatocellular carcinoma xenografts
[27]	iRGD	Doxorubicin	BGC-823 human gastric adenocarcinoma xenograft
[59]	iRGD	Intraperitoneal doxorubicin	Lovo-6-luc-1 human colon cancer and MKN45P gastric cancer xenografts
[74]	iRGD	Nanoparticles containing doxorubicin	4T1 mouse mammary cancer
[18]	iNGR	Doxorubicin	4T1 mouse mammary cancer
[75]	tLyP-1	Paclitaxel nanoparticles	C6 rat glioma
[76]	tLyp-1	Tumor targeted nanoparticles	C6 rat glioma (intracranial)